A preliminary clinical application of sICAM-1 RIA in three kinds of thyroid disease / 中华医学杂志(英文版)

<p><b>OBJECTIVE</b>To examine serum levels of sICAM-1 from normal controls and patients with thyroid diseases (simple goitre, Graves' disease or Hashimoto's thyroiditis) with (125)I-sICAM-1 RIA established in our lab.</p><p><b>METHODS</b>Using (125)I-sICAM-1 RIA, serum sICAM-1 levels of 400 healthy individuals as the normal group and 1020 patients with simple goitre (SG), Graves' disease (GD) or Hashimoto's thyroiditis (HT) were examined for a comporative chinical study.</p><p><b>RESULTS</b>The serum level of sICAM-1 (x +/- s) in the normal group was 168.43 +/- 36.23 micro g/L. There was no significant difference between the normal and SG groups (P > 0.05), whereas the serum levels of sICAM-1 in autoimmune thyroid diseases (GD or HT) were higher than those in the normal or SG groups (P < 0.05, respectively). After GD patients received one of three medical treatments, their serum sICAM-1 levels decreased (P < 0.05). After GD patients were treated and their thyroid function decreased to normal, their serum sICAM-1 levels were lower than those in relapsed GD patients (P < 0.05).</p><p><b>CONCLUSIONS</b>sICAM-1 RIA can be used to examine autoimmune thyroid diseases. Serum levels of sICAM-1 can be used as a parameter in diagnosing autoimmune thyroid disease and in evaluating the effects of therapy, drug administration or relapse in GD.</p>

Effect of Shouwu Yizhi Capsule on Gene Expression in Notch/Delta Signal Pathway of Vascular Dementia Model Rats / 中医杂志

Objective To investigate the effect and mechanism of Shouwu Yizhi Capsule (Capsule of Radix Polygoni Multiflori and Semen Coicis for dementia) on the Notch/Delta signal pathway in experimental rats with vascular dementia (VD). Methods The models were established with the modified Pulsinelli 4 vessel occlusion method. They were randomized into Shouwu Yizhi Capsule group,piracetam group,model group,and sham operation group with 14 rats in each group. Seven days after modeling,the Shouwu Yizhi Capsule group was administered intragastrically Shouwu Yizhi Capsule solution 0.08g/ml,the piracetam group was prescribed intragastrically piracetam solution 0.02g/ml,and the model and sham operation groups were given intragastrically normal saline. Twenty days later,the mRNA expression of HES1,Mash1,and ?-APP on Notch/Delta singal pathway was determined by real-time quantitative fluorescent PCR. Results Compared with the model and piracetam groups,the mRNA expression of HES1 the in Shouwu Yizhi Capsule group was significantly increased (P0.05). Conclusion Shouwu Yizhi Capsule could effectively activate the interaction of HES1,Mash1,and ?-APP on the Notch/Delta signal pathway,being the possible mechanism in the treatment of VD.